Post by
Noteable on Oct 25, 2022 5:23pm
Roche reports Q3 earnings - looks to Tecentriq for future
Roche's pharma revenues declined in the third quarter, but the Swiss major pharma company is looking towards their immune checkpoint inhibitor Tecentriq in adjuvant settings to boost future revenues.
Consequently, ONCY's pancreatic results from the Goblet Phase 2 clinical study could be what leads Roche's gains involving Teccentriq in combination with ONCY's pelareorep.
We will gain more insight into the positive results of the Goblet panceatic cancer cohort on November 11th at the SITC 2022 - 37th Annual Meeting.
https://www.oncolyticsbiotech.com/press-releases/detail/582/oncolytics-biotech-announces-upcoming-presentations-at
Comment by
Buckhenry on Oct 25, 2022 6:18pm
noteable gets the prestigious fickle finger award for posting the most stuff that has no bearing on oncy...
Comment by
Noteable on Oct 27, 2022 12:48pm
October 26, 2022 - https://www.evaluate.com/vantage/articles/news/trial-results/astra-beats-roche-twice-day
Comment by
jimsenior on Oct 31, 2022 10:07am
Added some shares this morning! Bonne chance.
Comment by
Noteable on Oct 31, 2022 12:12pm
All I saw on the TSX early this morning was Quebec based Desjardins Securities selling into the bid. I don't know how you "Machiavelli senior" could have been doing any "Bonne chance" buying.
Comment by
Noteable on Oct 31, 2022 12:39pm
Nonsense from me ?? !! Give your head a shake !